{"id":"NCT01309828","sponsor":"Takeda","briefTitle":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","officialTitle":"A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2011-03-07","resultsPosted":"2013-12-13","lastUpdate":"2013-12-13"},"enrollment":153,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Safety"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Olmesartan medoxomil and hydrochlorothiazide","otherNames":["Olmesartan medoxomil","Hydrochlorothiazide","Benicar hydrochlorothiazide","Olmetec Plus"]}],"arms":[{"label":"Azilsartan Medoxomil + Chlorthalidone","type":"EXPERIMENTAL"},{"label":"Olmesartan Medoxomil + Hydrochlorothiazide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate long term safety and tolerability of azilsartan medoxomil and chlorthalidone, once daily (QD), compared with olmesartan medoxomil and hydrochlorothiazide in hypertensive participants with moderate renal impairment.","primaryOutcome":{"measure":"Number of Participants With at Least 1 Adverse Event (AE)","timeFrame":"From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).","effectByArm":[{"arm":"Azilsartan Medoxomil + Chlorthalidone","deltaMin":68,"sd":null},{"arm":"Olmesartan Medoxomil + Hydrochlorothiazide","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":53,"countries":["Bulgaria","Germany","Latvia","Lithuania","Netherlands","Poland","Slovakia","Ukraine"]},"refs":{"pmids":["29504252"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":77},"commonTop":["Blood creatinine increased","Dizziness","Headache","Asthenia","Bronchitis"]}}